According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
Other research analysts have also issued research reports about the company. Barclays PLC lowered Smith & Nephew PLC from an overweight rating to an equal weight rating in a research report on Wednesday, August 10th. Beaufort Securities reiterated a hold rating on shares of Smith & Nephew PLC in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the stock. Smith & Nephew PLC currently has a consensus rating of Hold and an average price target of $37.00.
Shares of Smith & Nephew PLC (NYSE:SNN) opened at 31.38 on Tuesday. The company’s 50 day moving average price is $32.87 and its 200-day moving average price is $33.58. The firm has a market cap of $14.03 billion, a price-to-earnings ratio of 39.52 and a beta of 0.68. Smith & Nephew PLC has a 1-year low of $30.23 and a 1-year high of $36.11.
The company also recently disclosed a dividend, which will be paid on Tuesday, October 25th. Stockholders of record on Friday, October 7th will be paid a $0.236 dividend. The ex-dividend date of this dividend is Wednesday, October 5th.
Several hedge funds have recently bought and sold shares of SNN. Smithfield Trust Co. increased its stake in Smith & Nephew PLC by 1.1% in the second quarter. Smithfield Trust Co. now owns 3,660 shares of the company’s stock worth $125,000 after buying an additional 40 shares in the last quarter. Checchi Capital Advisers LLC increased its stake in Smith & Nephew PLC by 2.8% in the second quarter. Checchi Capital Advisers LLC now owns 5,892 shares of the company’s stock worth $202,000 after buying an additional 158 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Smith & Nephew PLC during the second quarter worth approximately $203,000. Toronto Dominion Bank increased its stake in Smith & Nephew PLC by 0.8% in the second quarter. Toronto Dominion Bank now owns 6,912 shares of the company’s stock worth $239,000 after buying an additional 55 shares in the last quarter. Finally, Financial Counselors Inc. increased its stake in Smith & Nephew PLC by 8.7% in the second quarter. Financial Counselors Inc. now owns 7,645 shares of the company’s stock worth $262,000 after buying an additional 611 shares in the last quarter. 5.86% of the stock is currently owned by institutional investors.
About Smith & Nephew PLC
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Smith & Nephew PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew PLC and related companies with MarketBeat.com's FREE daily email newsletter.